Bayesian multivariate probability of success using historical data with type I error rate control

被引:6
|
作者
Alt, Ethan M. [1 ,2 ]
Psioda, Matthew A. [3 ]
Ibrahim, Joseph G. [3 ]
机构
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA
[3] Univ North Ctirolina, Dept Biostat, 135 Dauer Dr, Chapel Hill, NC 27599 USA
关键词
Average probability of success; Multiplicity; Seemingly unrelated regression; CLINICAL-TRIALS; SAMPLE-SIZE; ASSURANCE;
D O I
10.1093/biostatistics/kxab050
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In clinical trials, it is common to have multiple clinical outcomes (e.g., coprimary endpoints or a primary and multiple secondary endpoints). It is often desirable to establish efficacy in at least one of multiple clinical outcomes, which leads to a multiplicity problem. In the frequentist paradigm, the most popular methods to correct for multiplicity are typically conservative. Moreover, despite guidance from regulators, it is difficult to determine the sample size of a future study with multiple clinical outcomes. In this article, we introduce a Bayesian methodology for multiple testing that asymptotically guarantees type I error control. Using a seemingly unrelated regression model, correlations between outcomes are specifically modeled, which enables inference on the joint posterior distribution of the treatment effects. Simulation results suggest that the proposed Bayesian approach is more powerful than the method of , which is commonly utilized in practice as a more powerful alternative to the ubiquitous Bonferroni correction. We further develop multivariate probability of success, a Bayesian method to robustly determine sample size in the presence of multiple outcomes.
引用
收藏
页码:17 / 31
页数:15
相关论文
共 49 条
  • [31] Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit
    Lachin, John M.
    CLINICAL TRIALS, 2009, 6 (06) : 565 - 573
  • [32] Assessment of Type I Error Rate Associated with Dose-Group Switching in a Longitudinal Alzheimer Trial
    Ghebretinsae, Aklilu Habteab
    Molenberghs, Geert
    Dmitrienko, Alex
    Offen, Walt
    Sethuraman, Gopalan
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (03) : 660 - 684
  • [33] Experiment-Wise Type I Error Control: A Focus on 2 x 2 Designs
    Frane, Andrew V.
    ADVANCES IN METHODS AND PRACTICES IN PSYCHOLOGICAL SCIENCE, 2021, 4 (01)
  • [34] Some clarifications regarding power and Type I error control for pairwise comparisons of three groups
    Frane, Andrew V.
    ELECTRONIC JOURNAL OF APPLIED STATISTICAL ANALYSIS, 2019, 12 (01) : 55 - 68
  • [35] Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials
    Ohigashi, Tomohiro
    Maruo, Kazushi
    Sozu, Takashi
    Gosho, Masahiko
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2022, 31 (07) : 1392 - 1404
  • [36] Bayesian Method of Borrowing Study-Level Historical Longitudinal Control Data for Mixed-Effects Models with Repeated Measures
    Li, Hong
    Jin, Man
    Chung, Yu-Che
    Zhong, Sheng
    Wang, Li
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (01) : 142 - 151
  • [37] Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs
    Smith, Claire L.
    Thomas, Zachary
    Enas, Nathan
    Thorn, Katharine
    Lahn, Michael
    Benhadji, Karim
    Cleverly, Ann
    PHARMACEUTICAL STATISTICS, 2020, 19 (03) : 276 - 290
  • [38] Using randomization tests to preserve type I error with response adaptive and covariate adaptive randomization
    Simon, Richard
    Simon, Noah Robin
    STATISTICS & PROBABILITY LETTERS, 2011, 81 (07) : 767 - 772
  • [39] Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence
    Maurer, Willi
    Jones, Byron
    Chen, Ying
    STATISTICS IN MEDICINE, 2018, 37 (10) : 1587 - 1607
  • [40] Bayesian Design of Clinical Trials Using Joint Cure Rate Models for Longitudinal and Time-to-Event Data
    Jiawei Xu
    Matthew A. Psioda
    Joseph G. Ibrahim
    Lifetime Data Analysis, 2023, 29 : 213 - 233